Particularly in the case of challenging cold tumors with an immunosuppressive TME, characterized by elevated levels of TGF-β1 and Treg cells, ULNPs offer distinctive application potential and may revolutionize the landscape of tumor immunotherapy. The gene discussed is TGFB1; the disease is neoplasm.